



HAL
open science

Tumor-Infiltrating Natural Killer Cells

Beatriz Cózar, Marco Greppi, Sabrina Carpentier, Emilie Narni-Mancinelli,
Laura Chiossone, Eric Vivier

► **To cite this version:**

Beatriz Cózar, Marco Greppi, Sabrina Carpentier, Emilie Narni-Mancinelli, Laura Chiossone, et al..
Tumor-Infiltrating Natural Killer Cells. *Cancer Discovery*, 2021, 11 (1), pp.34-44. 10.1158/2159-
8290.CD-20-0655 . hal-03566034

HAL Id: hal-03566034

<https://amu.hal.science/hal-03566034v1>

Submitted on 11 Dec 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Published in final edited form as:

Cancer Discov. 2021 January 01; 11(1): 34–44. doi:10.1158/2159-8290.CD-20-0655.

Tumor-infiltrating natural killer cells

Beatriz Cózar^{#a}, Marco Greppi^{#a,b}, Sabrina Carpentier^a, Emilie Narni-Mancinelli^c, Laura Chiossone^a, Eric Vivier^{a,c,d,*}

^aInnate Pharma Research Laboratories, Innate Pharma, Marseille, France

^bCenter of Excellence for Biomedical Research, University of Genoa, Genoa, Italy

^cAix Marseille University, CNRS, INSERM, CIML, Marseille, France

^dAPHM, Hôpital de la Timone, Service d'Immunologie, Marseille-ImmunoPôle, Marseille, France

These authors contributed equally to this work.

Abstract

Because of their potent antitumor activity and their proinflammatory role, natural killer (NK) cells are at the forefront of efforts to develop immuno-oncologic treatments. NK cells participate in immune responses to tumors by killing target cells and producing cytokines. However, in the immunosuppressive tumor microenvironment, NK cells become dysfunctional through exposure to inhibitory molecules produced by cancer cells, leading to tumor escape. We provide an overview of what is known about NK tumor infiltration and surveillance and about the mechanisms by which NK cells become dysfunctional.

Introduction

Natural killer (NK) cells are cytotoxic innate immune cells of lymphoid origin that were first described in 1973 as “null” killer cells after the discovery that a non-T non-B lymphocyte subset could efficiently kill antibody-coated cells (1). Two years later, the ability of NK cells to kill various types of tumor cells was reported, and the term “natural” killer cell was coined (2). NK cells play a role not only in the antitumor response, but also in defense against microbial infection (3). NK cells express diverse activating and inhibitory receptors (4), and the balance between the signals mediated by these receptors determines the outcome of NK-cell activation.

NK cells express cell surface inhibitory receptors that recognize MHC Class I (MHC-I) molecules. The most important inhibitory receptors are the members of the killer cell immunoglobulin-like receptor (KIR) family (5), and the CD94/ NKG2A heterodimer. Each

*Corresponding author Eric Vivier, ^aInnate Pharma Research Laboratories, Innate Pharma, Marseille, ^cAix Marseille University, CNRS, INSERM, CIML, Marseille, France, ^dAPHM, Hôpital de la Timone, Service d'Immunologie, Marseille-ImmunoPôle, vivier@ciml.uni-mrs.fr, phone: +33-(0)4-30303030.

The authors confirm that the figures are unpublished original works created by them and for the express purpose of publication in this Cancer Discovery review.

Disclosure of Potential Conflicts of Interest

B.C., S.C., L.C. and E.V. are employees of Innate Pharma.

individual expresses a specific set of KIRs. In total, 17 KIR genes have been described in humans, two of which are pseudogenes (6, 7). Each of these genes is highly polymorphic, with a total of 1,110 confirmed polymorphisms (IPD-KIR Database, Release 2.9.0), and at least twice that number of polymorphisms that have been reported. KIRs can be classified on the basis of their structure and function, according to two factors: (i) the number of immunoglobulin-like (Ig-like) domains, either two (KIR2D-) or three (KIR3D-), and (ii) the presence of a long or a short intracytoplasmic tail, assigned by the letter “L” for “long” or “S” for short. Inhibitory KIRs usually possess a long cytoplasmic tail (KIR2DL) whereas activating KIR possess a short one (KIR2DS), except for the activating KIR2DL4 that has a long cytoplasmic tail. Two main KIR haplotypes, A and B, have been described. The KIR A haplotypes encompass inhibitory KIR plus the activating KIR2DS4, and the KIR B haplotypes are characterized by the expression of at least one of the following activating KIR: KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, or KIR3DS1. Inhibitory KIRs contain immunoreceptor tyrosine-based inhibition motif (ITIM) sequences in the intracytoplasmic tail responsible for the inhibitory signal. KIRs containing ITIM sequences are the most common type of KIRs and are the canonical inhibitory KIRs responsible for inhibiting NK cells as far as MHC-I molecules are concerned, together with CD94/NKG2A. Activating KIRs can associate with immunoreceptor tyrosine-based activation motif (ITAM)-bearing molecules (KARAP/DAP12/TYROBP; refs. 8, 9) to transmit an activating signal. These activating KIRs have been associated with the outcome of autoimmune diseases, pregnancy-associated disorders, infectious diseases and cancers (10, 11).

According to the principle of “missing self” recognition (12), NK cells can eliminate targets that do not express sufficiently large numbers of MHC-I molecules. The expression of these molecules is often lost during viral infection and neoplastic transformation, enabling the cells to escape CD8⁺ T-cell immunosurveillance, which requires the presentation of antigens by MHC-I molecules (13). The down-regulation of these molecules renders the cells invisible to T cells, but with the loss of the main ligands for NK-cell inhibitory receptors (KIRs and CD94/NKG2A), NK cells are no longer inhibited and are more prone to activation via a plethora of activating receptors (14). The major activating NK-cell receptors are the natural cytotoxicity receptors (NCR) NKp30, NKp46, and NKp44, as well as CD16 and NKG2D. Other molecules, such as DNAX accessory molecule1 (DNAM1), 2B4, and NKp80, enhance NK-cell activity, mostly by acting as coreceptors. NK cells also express a large number of other inhibitory receptors regulating their activation status, including LILRB1 (also known as LIR1), CD161, KLRG1, SIGLEC7, SIGLEC9, PD-1, TIGIT, LAG3, and TIM3.

Human NK cells have heterogeneous phenotypes and functions. Two NK-cell subsets can be defined according to differential expression of the markers CD56 and CD16. The blood of healthy individuals contains two main NK cell populations: CD56dim CD16⁺ NK cells and CD56bright CD16⁻ NK cells. The CD56dim subset is considered as a mature cytotoxic population accounting for most of the circulating NK cells, whereas the CD56bright subset is less mature, mostly immunomodulatory, and mainly located in secondary lymphoid organs (15). Following the stimulation of activating receptors, CD56dim NK cells can kill other cells directly, but without prior priming. In contrast, CD56bright NK cells are less cytotoxic, but produce larger amounts of cytokines upon exposure to environmental stimuli,

such as IL1 β , IL2, IL12, IL15, and/or IL18 (16). The development of the two subsets is not yet fully understood, but the prevailing theory suggested that they correspond to two different steps of NK-cell maturation (17). We recently identified by single-cell profiling of human bone marrow NK cells that CD56bright CD127+ CD160– CD52+ cells, called NK0, can give rise to conventional NK2/CD56bright CD160+ CD52– cells and to NK1/CD56dim perforin^{hi} cells at steady state (Crinier et al., in press). NK cells were recently classified as belonging to the innate lymphoid cell (ILC) family, also encompassing helper-like ILCs (ILC1, ILC2, and ILC3) and lymphoid tissue inducer cells. Like ILC1, NK cells are capable of secreting type-1 cytokines such as IFN γ , TNF α , and granulocyte–macrophage colony-stimulating factor (GM-CSF). They are sometimes described as cytotoxic ILCs (18). ILC1 cells differ from NK cells principally in their lack of granule-dependent cytotoxicity. The other differences among these two cell types are relatively minor, and a degree of plasticity between the two subsets has been previously described (19–21). Most activating and inhibitory receptors expressed by ILC1s discovered to date are also expressed by NK cells (22), but these two subsets differ in terms of their localization in different organs. ILC1s are almost entirely absent from the bloodstream, instead being located mainly in the peripheral tissues, such as within the intestine (23). In terms of transcription factors, human ILC1s are described as EOMES–/lo T-bet+, whereas NK cells are described as EOMES+ T-bet+ (18). The conversion from cytotoxic NK to noncytotoxic ILC1 upon TGF β signaling has been described in mice (19, 20), but there is still no clear evidence that a similar process occurs in humans. Nevertheless, the identification of poorly cytotoxic, cytokine producing, tissue-resident EOMES– T-bet+ CD49a+ NK cells in the human liver (24) may provide evidence of a possible bridge between NK cells and ILC1s in humans resembling that described in mice.

To perform their functions correctly, NK cells must migrate to inflamed tissues. NK cells express a broad repertoire of chemokine receptors to control this migration. Resting CD56bright CD16– NK cells described as expressing CCR2 [recognizing CCL2 (MCP1), CCL7 (MCP-3), CCL12, CCL13 (MCP4), CCL16 (HCC-4)], and CCR5 (recognizing RANTES, MIP1 α , and MIP1 β) are targeted to lymph nodes via CCR7 (recognizing CCL19 and CCL21). They preferentially express CXCR3 [recognizing CXCL4, CXCL9 (MIG), CXCL10 (IP10)] and CXCL11 (I-TAC/IP9) and exhibit higher levels of CXCR4 (recognizing CXCL12 (SDF1; refs. 25, 26), when compared to the CD56dim subset. By contrast, CD56dim NK cells uniquely express CXCR1 (recognizing CXCL8; refs. 25, 26), CX3CR1 (recognizing CX3CL1; ref. 25) and ChemR23 [recognizing the peptide chemerin and the eicosapentaenoic acid-derived lipid mediator resolvin E1 (RvE1)]. CD56dim cells also express high levels of S1P5 (recognizing the bioactive lipid S1P) required for their egress from bone marrow and lymph nodes and also for their recruitment to inflamed tissues.

The ability of NK cells to kill cancer cells without prior sensitization results in these cells playing a role in tumor immunosurveillance, as demonstrated on multiple occasions. Evidence for the importance of NK cells in preventing tumor progression is the array of mechanisms used by tumor cells to decrease NK-cell immunosurveillance, and the requirement of these mechanisms for disease progression. In this review, we discuss NK-cell

infiltration into various types of tumor and the mechanisms underlying NK-cell dysfunction contributing to tumor evasion.

NK cell infiltration of solid tumors

At the tumor bed, NK cells may control tumor growth by interacting directly with tumor cells and through interplay with other immune cells (27). However, investigations of tumor biopsy specimens for several solid cancers have revealed little NK-cell infiltration into these tumors, although the methods used to identify tumor-infiltrating NK cells can be disputable. Nkp46 cell-surface expression is a marker of human NK cells encoded by the NCR1 gene (28). NCR1 expression is to date the marker providing the most reliable information about the presence of NK cells. NCR1 expression is weaker than that of other specific genes, such as CD4, CD8, and CD19, suggesting that NK cells infiltrate solid tumors in smaller numbers than CD4⁺ T, CD8⁺ T, and B cells, respectively. However, the presence of NK cells within the tumor microenvironment (TME) may be associated with a good prognosis. Indeed, low NK-cell numbers are observed in primary head and neck squamous cell carcinoma (HNSCC) tumor sections (29) and were associated with the insufficient tumor rejection. Higher levels of NCR1 expression at the tumor site are associated with better survival (30). There is also a positive correlation between the infiltration of NK cells and CD8⁺ T cells into the TME and prolonged survival in patients with colorectal carcinoma (31). In gastric and esophageal cancers (32), the proportion of CD56dim NK cells infiltrating tumors gradually decreases with disease progression in patients.

Non-small cell lung carcinoma (NSCLC) samples display low levels of NK-cell infiltration and an overexpression of NK inhibitory receptors. NK cells mostly infiltrate the tumor stroma, and smaller numbers of infiltrating NK cells in lung cancer tissues are linked to a larger primary cancer, smoking history, and poorer patient prognosis (33). Another study on NSCLC reported NK cells to be less frequent in cancer tissues than in normal lung tissue. The low percentage of NK cells in tumors results principally from a smaller number of cells from the CD16⁺ NK-cell subset (34).

An analysis of RNA-sequencing (RNA-seq) data for melanomas from The Cancer Genome Atlas (TCGA) showed that patients with metastatic cutaneous melanoma had better survival rates if their tumors showed signs of NK cell infiltration (35). Moreover, in patients with melanoma, higher NK-cell numbers were found to be correlated with the presence of protective stimulatory DCs in the tumor, patient responsiveness to anti-PD-1 immunotherapy, and better overall survival (36). Single-cell RNA-seq analysis on NK cells isolated from human melanoma metastases showed that NK cells were present in melanoma metastases, even in patients who failed to respond to checkpoint blockade (37).

We have also analyzed the various RNA-seq datasets available from the TCGA database of more than 10,000 tumor samples for 33 different types of cancer to assess NK-cell infiltration (Fig. 1). Informative genes significantly overexpressed by NK cells were selected to establish a NK-cell signature and to infer the abundance of these cell types in the tumor samples analyzed. A 13-gene signature, CD160, CD244, CHST12, CST7, GNLY, IL18RAP, IL2RB, KLRC1, KLRC3, KLRD1, KLRF1, PRF1, and XCL2 (38), to which NCR1 was added, was used as a metagene for NK-cell identification. For comparison, we also studied

infiltration of the CD8⁺ cytotoxic T-cell subset, which is also involved in tumor elimination. The T-cell metagene was defined as an 8-gene signature—CD3D, CD3E, CD8A, CD8B, KLRC1, KLRK1, GZMH, and CCL5—with the signature matrix file LM22 obtained with CIBERSORT (39) by selecting the genes with the highest weights for the population of interest. The specificity of the list was then validated with an immune cell compendium (40). These results revealed that the presence of tumor-infiltrating NK cells varies across tumor types and pave the way for the use of treatments targeting NK cells and/or T cells in specific cancer conditions, as most of the tissues with marked NK-cell infiltration were also infiltrated with T cells.

Dysfunctional NK cells

Several mechanisms operating within the TME alter NK cell function (Table 1; Fig. 2). NK-cell IFN γ production and the proportion of CD56^{bright} cells have been shown to be significantly lower in patients with prostate cancer than in controls (41). In an analysis of samples from patients with gastric cancer, the expression of activating and inhibitory receptors on NK cells was shown to be similar in tumor tissues and the surrounding nontumor tissues. However, the effector functions of NK cells were impaired, as these cells had lower levels of IFN γ , TNF α , and Ki-67 in gastric cancer (42). The percentages of tumor-infiltrating NK cells were significantly lower than in controls and were correlated with tumor progression and poor overall patient survival. In hepatocellular carcinoma (HCC) tissues, NK cells have poor cytotoxicity and an impaired capacity to produce IFN γ (43). In human liver cancer, tumor-infiltrating NK cells display mitochondrial alterations (smaller size and fragmentation) not observed in peripheral NK cells outside the tumor (44). This fragmentation is correlated with lower cytotoxicity and NK-cell counts, resulting in impaired tumor control and evasion from NK-cell immunosurveillance, which was found to have a direct negative impact on patient prognosis. A microarray expression assay on tumor slices from chemotherapy resistant breast cancer samples showed a downregulation of NK cell-mediated cytotoxicity genes (45). In another study, the proportion of NK cells in mammary tumors was found to be similar to that in paired healthy mammary tissues. However, NK cells in malignant and healthy tissues had different phenotypes, with CD56^{bright} cells being the more prevalent in the tumor than in healthy control tissues (46).

Sustained exposure to high concentrations of NKG2D ligands (NKG2DL) is often but not always associated with a systematic decrease in NKG2D expression and the induction of tolerance in NK cells, leading to an evasion of immune surveillance (47, 48). The cumulative levels of these ligands in plasma have been implicated in the inhibition of NK-cell activity and shown to correlate with disease progression and tumor load in several types of cancer, including HNSCCs and melanoma (29, 49, 50). However, the impact of the chronic interaction between NK cells and NKG2DL-expressing cells remains a matter of debate. For instance, the soluble variant of the murine high-affinity NKG2D ligand MULT1 was found to have the opposite effect on NK cells, stimulating tumor rejection and increasing NKG2D membrane expression in an in vivo melanoma model (51). Of note, a subset of acute myeloid leukemia (AML) cells from patients lacks NKG2D ligand expression and can overcome NK cell-mediated killing, with repercussions for disease progression (52).

In breast cancer samples and studies of pancreatic cancer cells, NK cells have been shown to have low levels of expression of the activating receptors NKp30, NKG2D, NKp46, DNAM1, and CD16, and high levels of expression of inhibitory receptors, such as NKG2A, this profile being correlated with an impairment of NK-cell cytotoxicity (46). NK cells from patients with chronic B lymphocytic leukemia (B-CLL) display a small but significant downregulation of NKp30 (53, 54), leading to a poorer prognosis. Patients with AML have an NK-cell phenotype in which the NKp30 (55) and NKp46 (55, 56) receptors are weakly expressed. High levels of NKp46 expression at diagnosis were found to be correlated with a better prognosis in patients with AML (57). Patients with CLL have higher levels of soluble ligands for NKp30 and NKG2D than healthy individuals, which can lead to the suppression of NK-cell cytotoxicity and the promotion of CLL evasion from NK cells (58). The α -disintegrin and metalloproteinases ADAM 10 and 17 expressed on the surface of tumor cells have been reported to participate in the shedding of B7-H6 (59). The presence of the soluble form of the NKp30 ligand B7-H6 has also been associated with lower levels of NKp30 expression on NK cells in various cancers (60–62). CD16 is a key receptor in antigen-dependent cell cytotoxicity (ADCC) and has been shown to be less strongly expressed in patients with breast cancer than in healthy individuals (63). In patients with melanoma, the major infiltrating NK-cell subset is the CD56 dim CD16 – subset (64). The metalloprotease ADAM17 is a regulatory checkpoint of the CD16A receptor in NK cells. Upon activation, it can induce CD16A cleavage, hampering its signaling and NK-cell function. The proportions of the activating receptor DNAM1 (CD226) and the adhesion molecule CD96 on NK cells are significantly lower in pancreatic tumor samples than in control samples, and the downregulation of these molecules is associated with tumor histologic grade and lymph node metastasis (65).

PD-1 has been well characterized as an exhaustion marker on T cells but can also be expressed on NK cells (66). Its expression on NK cells has been called into question (67), but the likelihood of PD-1 detection on NK cells may be highly dependent on the choice of reagents (68), and functional analyses often demonstrate the functionality of PD-1 on NK cells. Indeed, the PD-1+ NK cells infiltrating head and neck tumors have an exhausted phenotype. PD-1 is overexpressed on the surface of NK cells from digestive cancers, and PD-1/PD-L1 antibody blockade restores NK function in vitro (69). Intratumoral TIM3+ PD-1+ NK cells from patients with various cancers have defective IFN γ and granzyme B secretion and are less cytotoxic than TIM3–PD-1– NK cells (70). In colon tumor samples, levels of PD-1 and CTLA4 expression are very low on tumor-infiltrating NK cells. However, levels of TIGIT expression are significantly higher on NK cells in the tumor than on those outside the tumor, and this feature is associated with NK-cell exhaustion (71). CD155 acts as a ligand of both the stimulatory receptor DNAM1 and the inhibitory receptor TIGIT. It has been found to be overexpressed in various types of cancer, and its interaction with DNAM1 can induce its downregulation (72–74).

The inhibitory receptor NKG2A and its ligand HLA-E are frequently overexpressed in many types of tumor. In HCC (75) and colorectal carcinoma (76), HLA-E overexpression is correlated with NK-cell exhaustion and poor prognosis. Moreover, NKG2A blockade has been shown to enhance antitumor immunity by promoting both NK-cell and CD8+ T-cell effector functions in mice and humans (77).

NK cells are particularly important for metastasis prevention (78), and NK-cell dysfunction is associated with an increase in cancer metastasis in various cancer types. In breast cancer, GSK3 β (glycogen synthase kinase-3) inactivation has been linked with NK-cell dysfunction and is considered to be responsible for metastasis formation (79). In gastric cancer, NK-cell dysfunction, in terms of lower levels of activating receptor expression on circulating NK cells, is correlated with tumor progression (80). In addition, mouse models with less efficient NK-cell migration to the tumor due to a lack of heparanase (81) display higher rates of metastasis, and the induction of NK-cell invasion of the tumor by the deletion of atypical chemokine receptor 2 (ACKR2), which competes with chemokine receptor CCR4, causes a significant decrease in metastasis (82). Similar results were obtained in a study in which TRAIL activation by dose-dependent ONC201 (an orally active antitumor agent) administration increased NK-cell invasion and cytotoxicity, reducing the rate of metastasis formation (83).

The tumor microenvironment affects NK cell functions

The tumor microenvironment can sustain tumor growth and influence immune escape and cancer progression. Most solid tumors contain regions of permanent or transient hypoxia due to changes in vascularization and restricted access to nutrients and oxygen. Hypoxia has been demonstrated to limit NK-cell activity (84). The fragmentation of NK-cell mitochondria is one of the mechanisms by which hypoxia decreases NK-cell survival and function (44). Other studies in digestive tumors reported the production of abundant H₂O₂ in the TME, linked to a decrease in the infiltration of CD56dim NK cells (32). Indeed, cytotoxic CD56dim cells are more susceptible to H₂O₂-induced apoptosis than CD56bright cells. Another mechanism of tumor evasion has been demonstrated for platelets. Platelet cloaking of tumor cells can promote the shedding from the tumor cell surface of the NKG2D ligands MICA and MICB, which are released into the TME and may decrease NKG2D expression on NK cells (85). Moreover, NK-cell exposure to the H₂O₂ produced within the TME impairs ADCC activity and decreases CD56dim NK-cell infiltration (32). Indoleamine 2, 3-dioxygenase 1 (IDO1) is a metabolic enzyme that converts the essential amino acid tryptophan into downstream molecules known as kynurenines. IDO1 is overexpressed in various tumors and is responsible for immunosuppression and NK and T-cell inhibition (86, 87). The TME also affects NK-cell functionality through the production of soluble factors. TGF β is a major immunosuppressive cytokine that decreases the antitumor activity of NK cells. In glioblastoma, for example, TGF β has been described as an agent potentially capable of decreasing the expression of the major NK-cell activating molecules (88). In acute lymphoblastic leukemia, the coculture of healthy donor NK cells with ALL blasts results in a suppression of the cytotoxic activity of the NK cells through the release of soluble factors, including TGF β 1 (89). Patients with lung and colorectal cancers have higher levels of TGF β 1 in their blood than healthy volunteers, which has been shown to decrease the level of NKG2D expression on NK cells (90). STAT3 is a key regulator of the transcription of genes encoding factors involved in cell growth and differentiation, including TGF β , and is constitutively activated in various primary tumors and cell lines. In esophageal squamous cell carcinoma, STAT3 signaling also plays a key role in IL6 and IL8 secretion by tumor cells, leading to the downregulation of activating receptors (NKp30 and NKG2D) on the surface of NK cells, impairing their function (91). Prostaglandin-E2 (PGE2) is a small

molecule that is upregulated in various cancers and can decrease NK-cell cytotoxicity (92, 93). Various cell types residing in the TME can downregulate the immune response. These cells include fibroblasts, stromal cells, regulatory T cells (Tregs) and the so-called myeloid-derived suppressor cells (MDSC). Tregs exert immunosuppressive effects by inhibiting CD8⁺ T cells and NK cells directly or via the secretion of TGF β and IL10. Treg cells also influence NK-cell inhibition in cancer. High Treg cell numbers are correlated with poorer NK-cell function in patients with gastrointestinal cancer (94), and MDSCs from patients with cancer significantly inhibit NK cell-mediated ADCC by producing nitric oxide (95).

Concluding remarks

NK cells are involved in the immune response to tumors, participating in their elimination. This has led to their consideration as potential targets for cancer immunotherapy. However, malignant transformation often affects the expression or function of inhibitory and activating NK-cell receptors, with a direct impact on NK-cell cytotoxicity. Various mAbs directed against key checkpoint ligands and their receptors have been designed and produced for preventing NK-cell inactivation via the blocking of inhibitory receptors. Examples include antibodies directed against NKG2A, such as monalizumab, and against TIGIT, which have already entered clinical trials. Other therapeutic approaches aim to increase the efficacy of tumor cell recognition by NK cells. In this case, antibodies against tumor antigens, such as EGFR, can enhance ADCC by the immune cells. Another strategy aiming to prevent the shedding of the NKG2A ligands MICA and MICB has shown promising results in humanized melanoma models (96). Recent investigations have also focused on increasing the infiltration and recruitment of immune cells to the tumor site through the development of antibodies against soluble factors secreted by the tumor, such as TGF β . Anti-TGF β antibodies have already progressed to clinical trials for various solid cancers, where they are being tested alone and in combination with anti-PD-1 agents (97). An ability to assess immune cell infiltration into tumors and the receptor repertoires of the infiltrating immune effector cells would improve predictions of clinical response and make it possible to design personalized immunotherapies based on a better stratification of patients with cancer. The factors critical to the success of future treatments thus include the development of ways of increasing tumor infiltration and rescuing the function of immune effector cells, such as with NK cell engagers (98). In the case of NK cells, combination therapies addressing both these issues and the targeting of adaptive immune effectors may be particularly beneficial.

Acknowledgments

The E. Vivier laboratory at CIML and Assistance-Publique des Hôpitaux de Marseille is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC, grant agreement no. 694502 and MInfla-TILC, grant agreement no. 875102 - MInfla-Tilc), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie ITN grant agreement no. 765104-MATURE-NK, the Agence Nationale de la Recherche including the PIONEER Project (ANR-17-RHUS-0007), MSDAvenir, Innate Pharma and institutional grants to the CIML (INSERM, CNRS, and Aix-Marseille University), and to Marseille Immunopole.

References

1. Greenberg AH, Hudson L, Shen L, Roitt IM. Antibody-dependent cell mediated cytotoxicity due to a "Null" Lymphoid Cell. *Nat New Biol.* 1973; 242:111–3. [PubMed: 4541031]

2. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. *Eur J Immunol.* 1975; 5:112–7. [PubMed: 1234049]
3. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A. Human NK cell response to pathogens. *Semin Immunol.* 2014; 26:152–60. [PubMed: 24582551]
4. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. *Cytometry A.* 2013; 83A:702–13.
5. Harel-Bellan A, Quillet A, Marchiol C, DeMars R, Tursz T, Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. *Proc Natl Acad Sci U S A.* 1986; 83:5688–92. [PubMed: 2426704]
6. Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. *Hum Immunol.* 2003; 64:648–54. [PubMed: 12770798]
7. Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. *Front Immunol.* 2019; 10:1179. [PubMed: 31231370]
8. Lanier LL, Cortiss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. *Nature.* 1998; 391:703–7. [PubMed: 9490415]
9. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. *J Immunol.* 1997; 158:5083–6. [PubMed: 9164921]
10. Blunt MD, Khakoo SI. Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use. *Int J Immunogenet.* 2020; 47:1–12. [PubMed: 31755661]
11. van der Ploeg K, Chang C, Ivarsson MA, Moffett A, Wills MR, Trowsdale J. Modulation of human leukocyte antigen-C by human cytomegalovirus stimulates KIR2DS1 recognition by natural killer cells. *Front Immunol.* 2017; 8:29. [PubMed: 28184222]
12. Ljunggren HG, Kärre K. In search of the “missing self”: MHC molecules and NK cell recognition. *Immunol Today.* 1990; 11:237–44. [PubMed: 2201309]
13. Garrido F. MHC/HLA class I loss in cancer cells. *Adv Exp Med Biol.* 2019; 1151:15–78. [PubMed: 31140106]
14. Sivori S, Vitale M, Bottino C, Marcenaro E, Sanseverino L, Parolini S, et al. CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. *Eur J Immunol.* 1996; 26:2487–92. [PubMed: 8898964]
15. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. *Immunity.* 2017; 47:820–33. [PubMed: 29166586]
16. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. *Eur J Immunol.* 2001; 31:3121–6. [PubMed: 11592089]
17. Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, et al. CD56 bright CD16 – killer Ig-like receptor – NK cells display longer telomeres and acquire features of CD56 dim NK cells upon activation. *J Immunol.* 2007; 178:4947–55. [PubMed: 17404276]
18. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells—a proposal for uniform nomenclature. *Nat Rev Immunol.* 2013; 13:145–9. [PubMed: 23348417]
19. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. *Nat Immunol.* 2017; 18:1004–15. [PubMed: 28759001]
20. Cortez VS, Ulland TK, Cervantes-Barragan L, Bando JK, Robinette ML, Wang Q, et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF- β signaling. *Nat Immunol.* 2017; 18:995–1003. [PubMed: 28759002]

21. Marquardt N, Béziat V, Nyström S, Hengst J, Ivarsson MA, Kekäläinen E, et al. Cutting edge: identification and characterization of human intrahepatic CD49a + NK cells. *J Immunol.* 2015; 194:2467–71. [PubMed: 25672754]
22. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. *Nat Rev Immunol.* 2018; 18:671–88. [PubMed: 30209347]
23. Kim CH, Hashimoto-Hill S, Kim M. Migration and tissue tropism of innate lymphoid cells. *Trends Immunol.* 2016; 37:68–79. [PubMed: 26708278]
24. Sun H, Liu L, Huang Q, Liu H, Huang M, Wang J, et al. Accumulation of tumor-infiltrating cd49a nk cells correlates with poor prognosis for human hepatocellular carcinoma. *Cancer Immunol Res.* 2019; 7:1535–46. [PubMed: 31311791]
25. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56 + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. *J Immunol.* 2001; 166:6477–82. [PubMed: 11359797]
26. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ. Evidence for NK cell subsets based on chemokine receptor expression. *J Immunol.* 2006; 177:7833–40. [PubMed: 17114454]
27. Malmberg K, Carlsten M, Björklund A, Sohlberg E. Natural killer cell mediated immunosurveillance of human cancer. *Semin Immunol.* 2017; 31:20–9. [PubMed: 28888619]
28. Walzer T, Bléry M, Chaix J, Fuseri N, Chasson L, Robbins SH, et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. *Proc Natl Acad Sci U S A.* 2007; 104:3384–9. [PubMed: 17360655]
29. Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. *Front Immunol.* 2017; 8:387. [PubMed: 28443091]
30. Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1^{hi} NK cells in head and neck cancer patients. *Cancer Immunol Res.* 2018; 6:1548–60. [PubMed: 30282672]
31. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Drosner R, Caratelli S, et al. Nk cells and T cells cooperate during the clinical course of colorectal cancer. *Oncoimmunology.* 2014; 3:1–6.
32. Izawa S, Kono K, Mimura K, Kawaguchi Y, Watanabe M, Maruyama T, et al. H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. *Cancer Immunol Immunother.* 2011; 60:1801–10. [PubMed: 21811786]
33. Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, et al. NK cell phenotypic modulation in lung cancer environment. *PLoS One.* 2014; 9:e109976 [PubMed: 25299645]
34. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, et al. Immune cell composition in human non-small cell lung cancer. *Front Immunol.* 2018; 9:3101. [PubMed: 30774636]
35. Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hedyeh-Zadeh S, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. *Cancer Immunol Res.* 2019; 7:1162–74. [PubMed: 31088844]
36. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. *Nat Med.* 2018; 24:1178–91. [PubMed: 29942093]
37. De Andrade LF, Lu Y, Luoma A, Ito Y, Pan D, Pyrdol JW, et al. Discovery of specialized NK cell populations infiltrating human melanoma metastases. *JCI Insight.* 2019; 4:e133103
38. Crinier A, Milpied P, Escalière B, Piperoglou C, Galluso J, Balsamo A, et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. *Immunity.* 2018; 49:971–86. [PubMed: 30413361]
39. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods.* 2015; 12:453–7. [PubMed: 25822800]
40. Carpentier S, Romagné F, Vivier E. A comprehensive approach to gene expression profiling in immune cells. *Methods Enzymol.* 2020; 636:1–47. [PubMed: 32178815]

41. Koo KC, Shim DH, Yang CM, Lee S-B, Kim SM, Shin TY, et al. Reduction of the CD16–CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. *PLoS One*. 2013; 8:e78049 [PubMed: 24223759]
42. Peng LS, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, et al. Tumor-associated monocytes/macrophages impair NK-cell function via TGFβ1 in human gastric cancer. *Cancer Immunol Res*. 2017; 5:248–56. [PubMed: 28148545]
43. Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, et al. Liver-infiltrating CD11b-CD27-NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. *Cell Mol Immunol*. 2017; 14:819–29. [PubMed: 27321064]
44. Zheng X, Qian Y, Fu B, Jiao D, Jiang Y, Chen P, et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. *Nat Immunol*. 2019; 20:1656–67. [PubMed: 31636463]
45. Garcia-Chagollan M, Carranza-Torres IE, Carranza-Rosales P, Guzmán-Delgado NE, Ramírez-Montoya H, Martínez-Silva MG, et al. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. *Technol Cancer Res Treat*. 2018; 17:1533033818764499 [PubMed: 29558872]
46. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *J Clin Invest*. 2011; 121:3609–22. [PubMed: 21841316]
47. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. *Blood*. 2008; 111:3571–8. [PubMed: 18198346]
48. Thompson TW, Kim AB, Li PJ, Wang J, Jackson BT, Huang KTH, et al. Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. *Elife*. 2017; 6:e30881 [PubMed: 29231815]
49. Klöß S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, et al. Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. *Oncoimmunology*. 2015; 4:e1055993 [PubMed: 26451327]
50. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. *Clin Cancer Res*. 2009; 15:5208–16. [PubMed: 19671853]
51. Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. *Science*. 2015; 348:136–9. [PubMed: 25745066]
52. Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. *Nature*. 2019; 572:254–9. [PubMed: 31316209]
53. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. *J Clin Immunol*. 2012; 32:632–46. [PubMed: 22318393]
54. Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sébahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. *Immunology*. 2012; 135:151–7. [PubMed: 22044312]
55. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction. *Blood*. 2007; 109:323–30. [PubMed: 16940427]
56. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. *Haematologica*. 2014; 99:836–47. [PubMed: 24488563]
57. Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, et al. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. *Oncoimmunology*. 2017; 6:e1307491 [PubMed: 29209559]
58. Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. *Blood*. 2013; 121:3658–65. [PubMed: 23509156]

59. Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. *Cancer Res.* 2014; 74:3429–40. [PubMed: 24780758]
60. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. *Sci Transl Med.* 2015; 7 283ra55
61. Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. *Oncoimmunology.* 2015; 4 e1001224 [PubMed: 26137398]
62. Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni A, et al. Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma. *Hepatology.* 2019; 69:1165–79. [PubMed: 30153337]
63. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. *J Transl Med.* 2013; 11:307. [PubMed: 24330813]
64. Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, et al. CD56dim CD16– natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon- α . *Front Immunol.* 2019; 10:14. [PubMed: 30761123]
65. Peng YP, Xi CH, Zhu Y, Di Yin L, Wei JS, Zhang JJ, et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. *Oncotarget.* 2016; 7:66586–94. [PubMed: 27626490]
66. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. *J Allergy Clin Immunol.* 2017; 139:335–46. [PubMed: 27372564]
67. Judge SJ, Dunai C, Aguilar EG, Vick SC, Sturgill IR, Khuat LT, et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. *J Clin Invest.* 2020; 130:3051–68. [PubMed: 32134744]
68. Del Zotto G, Antonini F, Pesce S, Moretta F, Moretta L, Marcenaro E. Comprehensive phenotyping of human PB NK cells by flow cytometry. *Cytometry A.* 2020; 97:891–9. [PubMed: 32198974]
69. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell mediated anti-tumor function and indicates poor prognosis in digestive cancers. *Oncogene.* 2017; 36:6143–53. [PubMed: 28692048]
70. Seo H, Jeon I, Kim BS, Park M, Bae EA, Song B, et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-Tumour immunity in MHC class I-deficient tumours. *Nat Commun.* 2017; 8:15776. [PubMed: 28585539]
71. Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. *Nat Immunol.* 2018; 19:723–32. [PubMed: 29915296]
72. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren H-G, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. *J Immunol.* 2009; 183:4921–30. [PubMed: 19801517]
73. Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y, et al. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. *Cancer Sci.* 2010; 101:1326–30. [PubMed: 20331633]
74. Li Y-C, Zhou Q, Song Q-K, Wang R-B, Lyu S, Guan X, et al. Overexpression of an immune checkpoint (CD155) in breast cancer associated with prognostic significance and exhausted tumor-infiltrating lymphocytes: a cohort study. *J Immunol Res.* 2020; 2020 3948928 [PubMed: 32411795]
75. Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. *Oncoimmunology.* 2017; 6 e1264562 [PubMed: 28197391]
76. Zhen ZJ, Ling JY, Cai Y, Luo WB, He YJ. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. *Med Oncol.* 2013; 30:482. [PubMed: 23377987]

77. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell*. 2018; 175:1731–43. [PubMed: 30503213]
78. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, et al. NKp46 receptor-mediated interferon- γ production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis. *Immunity*. 2018; 48:107–19. [PubMed: 29329948]
79. Jin F, Wu Z, Hu X, Zhang J, Gao Z, Han X, et al. The PI3K/Akt/ GSK-3 β /ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility. *Cancer Biol Med*. 2019; 16:38–54. [PubMed: 31119045]
80. Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. *J Immunol Res*. 2018; 2018:6248590 [PubMed: 30255106]
81. Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, et al. NK cell heparanase controls tumor invasion and immune surveillance. *J Clin Invest*. 2017; 127:2777–88. [PubMed: 28581441]
82. Hansell CAH, Fraser AR, Hayes AJ, Pinggen M, Burt CL, Lee KM, et al. The atypical chemokine receptor Akr2 constrains NK cell migratory activity and promotes metastasis. *J Immunol*. 2018; 201:2510–9. [PubMed: 30158126]
83. Wagner J, Leah Kline C, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. *J Clin Invest*. 2018; 128:2325–38. [PubMed: 29533922]
84. Terrén I, Orrantía A, Vitallé J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. *Front Immunol*. 2019; 10:2278. [PubMed: 31616440]
85. Cluxton CD, Spillane C, O’Toole SA, Sheils O, Gardiner CM, O’Leary JJ. Suppression of Natural Killer cell NKG2D and CD226 antitumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. *PLoS One*. 2019; 14:e0211538 [PubMed: 30908480]
86. Pietra G, Vitale M, Moretta L, Mingari MC. How melanoma cells inactivate NK cells. *Oncoimmunology*. 2012; 1:974–5. [PubMed: 23162776]
87. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. *Int J Oncol*. 2012; 40:929–34. [PubMed: 22179492]
88. Close HJ, Stead LF, Nsengimana J, Reilly KA, Droop A, Wurdak H, et al. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. *Clin Exp Immunol*. 2020; 200:33–44. [PubMed: 31784984]
89. Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, et al. The TGF- β /SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. *Leukemia*. 2016; 30:800–11. [PubMed: 26621337]
90. Lee J-C, Lee K-M, Kim D-W, Heo DS. Elevated TGF- β 1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. *J Immunol*. 2004; 172:7335–40. [PubMed: 15187109]
91. Wu J, Gao FX, Wang C, Qin M, Han F, Xu T, et al. IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. *J Exp Clin Cancer Res*. 2019; 38:321. [PubMed: 31324197]
92. Park A, Lee Y, Kim MS, Kang YJ, Park YJ, Jung H, et al. Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape through the suppression of natural killer (NK) cell cytotoxicity and NK cell differentiation. *Front Immunol*. 2018; 9:1859. [PubMed: 30140269]
93. Galland S, Vuille J, Martin P, Letovanec I, Caignard A, Fregni G, et al. Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets. *Cell Rep*. 2017; 20:2891–905. [PubMed: 28930684]
94. Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- β -dependent manner. *J Exp Med*. 2005; 202:1075–85. [PubMed: 16230475]

95. Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor-mediated natural killer cell function. *Clin Cancer Res.* 2018; 24:1891–904. [PubMed: 29363526]
96. De Andrade LF, En Tay R, Pan D, Luoma AM, Ito Y, Badrinath S, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. *Science.* 2018; 359:1537–42. [PubMed: 29599246]
97. Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, et al. α -PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α -TGF β antibody to promote durable rejection and immunity in squamous cell carcinomas. *J Immunother Cancer.* 2019; 7:62. [PubMed: 30832732]
98. Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. *Cell.* 2019; 177




Figure 2. Mechanisms involved in NK cell dysfunction in the tumor bed.

Tumor cells can modify the extracellular environment by producing immunosuppressive cytokines, such as TGF β , which decrease NK-cell functionality and infiltration. The tumor cells can also affect NK functionality by promoting hypoxic conditions leading to an activation of the intracellular protein mTOR-DRP1 causing mitochondrial fragmentation in the NK cell. Mesenchymal stem cells (MSC) and tumor cells produce prostaglandin-E2 (PGE2), which decreases NK cytotoxicity. Regulatory T cells (Treg) can directly suppress NK-cell function or indirectly influence NK-cell inhibition by secreting IL10 and TGF β . Myeloid-derived suppressor cells (MDSC) can inhibit NK-cell ADCC via the secretion of nitric oxide (NO). Tumor cell–secreted IL6 and IL8 impair the activity and function of NK cells via STAT3, suppressing expression of the NK cell–activating receptors NKp30 and NKG2D. In many human tumors, a downregulation of the expression of the activating receptors NKp46, NKp30, NKG2D, DNAM1, and CD16 has been observed on NK cells, with a direct negative impact on NK-cell activation and antitumor function. Moreover, tumor cells have been found to overproduce and shed the ligands of these activating receptors (e.g., NKp30 ligand B7-H6 and NKG2D ligands MICA and MICB), inducing an inhibition of activating signaling pathways. The metalloprotease ADAM17 expressed on the surface of tumor cells in addition to participating in the shedding of B7-H6 is also able to induce the cleavage of the activating CD16. Tumor cells are able to attract platelets, which in turn promote the release of NK2GDL and TGF β , contributing to the suppression of NK-cell function. Tumor cells can also overexpress ligands (e.g., CD155, PD-L1, and HLA-E) of NK

inhibitory receptors and increase the expression of some of these receptors, such as TIGIT, PD-1, and NKG2A, leading to alterations of the function of infiltrating NK cells.

Table 1

Mechanisms of NK cell dysfunction.

Mechanism	Cause	Evidence	Cancer type	Species	Ref.
Loss of expression/function of activating NK cell receptors	NKG2D downregulation	Downregulation of NKG2D on peripheral NK cells from patients	Breast cancer	Human	Mamessier, <i>et al.</i> 2011 J Clin Invest.
		Decrease in NKG2D surface expression on circulating NK cells in patients	Lung and colorectal cancer	Human	Lee, <i>et al.</i> 2004 J Immunol
	Impairment of NKG2D-dependent activation by NKG2DL	Removal of shed NKG2DL ligands from the plasma of HNSCC patients restores NK cell function <i>in vitro</i>	Head and neck cancer	Human	Weil, <i>et al.</i> 2017 Front Immunol
		Tumor cells can attract platelets <i>in vitro</i> , promoting the release of NKG2DL and suppressing NK cell function	Ovarian cancer and melanoma	Human	Cluxton, <i>et al.</i> 2019 Plos One
		Elevated levels of soluble ULBP2 ligand are associated with poorer prognosis	Melanoma	Human	Paschen, <i>et al.</i> 2009 Clin Cancer Res
		Lack of NKG2DL expression by a subset of AML cells from patient leads to tumor evasion	Acute myeloid leukemia	Human	Paczulla, <i>et al.</i> 2019 Nature
		Increase in MICA and TGFβ1 levels in the plasma of HNSCC patients impaired NKG2D-dependent cytotoxicity against tumor cells	Head and neck cancer	Human	Klöß, S. <i>et al.</i> 2015 Oncoimmunology
		Downregulation of NKp46 on peripheral NK cells from patients relative to healthy donors	Acute myeloid leukemia	Human	Fauriat, <i>et al.</i> 2007 Blood
	NKp46 downregulation	Patients with higher levels of NKp46 expression at diagnosis had a better prognosis than patients with NKp46 downregulation	Acute myeloid leukemia	Human	Stringaris, <i>et al.</i> 2014 Haematologica
			Acute myeloid leukemia	Human	Chretien, <i>et al.</i> 2017 Oncoimmunology
	NKp30 downregulation	Downregulation of NKp30 on peripheral NK cells from patients	Breast cancer	Human	Mamessier, <i>et al.</i> 2011 J Clin Invest.
			Chronic lymphocytic leukemia	Human	Veullen, <i>et al.</i> 2012 J Clin Immunology
Decrease in NKp30 expression on NK cells isolated from the peripheral blood of patients		Acute myeloid leukemia	Human	Fauriat, <i>et al.</i> 2007 Blood	
Patients from the poor prognosis group had lower levels of NKp30 expression on peripheral NK cells		Chronic lymphocytic leukemia	Human	Costello, <i>et al.</i> 2012 Immunology	
Impairment of tumor recognition through metalloprotease-mediated shedding of B7-H6, leading to an increase in blood B7-H6 levels		Melanoma	Human	Schlecker, <i>et al.</i> 2014 Cancer Research	
Soluble B7-H6 levels in the patients' blood correlated with the downregulation of NKp30 expression and a poorer prognosis		Neuroblastoma	Human	Semeraro, <i>et al.</i> 2015 Science Transl. Medicine	

Mechanism	Cause	Evidence	Cancer type	Species	Ref.
Overexpression/overstimulation of inhibitory receptors			Ovarian carcinoma	Human	Pesce, <i>et al.</i> 2015 Oncoimmunology
			Hepatocellular carcinoma	Human	Mantovani, <i>et al.</i> 2018 Hepatology
		DNAM-1 (CD226) downregulation	Decrease in the percentage of CD226 ⁺ CD96 ⁺ NK cells associated with tumor histological grade and lymph node metastasis	Human	Peng, <i>et al.</i> 2016 Oncotarget
		CD16 downregulation	Low levels of CD16 expression on CD56 ⁺ cells in all patient cohorts	Human	Petricevic, <i>et al.</i> 201. 3 J Trans Med
			CD56 ^{dim} CD16 ⁻ NK cells are the dominant subset in the tumor microenvironment	Human	Vujanovic, <i>et al.</i> 2019 Front Immunol
		PD-1 expression	Increase in PD-1 expression on peripheral NK cells indicates poorer survival in esophageal and liver cancers	Human	Liu, <i>et al.</i> 2017 Oncogene
			Intratumoral Tim-3 ⁺ PD-1 ⁺ NK cells from patients less cytotoxic than Tim-3 ⁻ PD-1 ⁻ NK cells	Human	Seo, <i>et al.</i> 2017 Nat Commun
		PD-1 ligands overexpression	PD-L1 ligation of PD-1 ⁺ NK cells decreased their activation status	Human	Concha-Benavente, <i>et al.</i> 2018 Cancer Immunol Res.
		NKG2A	NKG2A is overexpressed on peripheral NK cells and associated with impaired NK cell effector function	Human	Stringaris, <i>et al.</i> 2014 Haematologica
			NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion	Human	Sun, <i>et al.</i> Oncoimmunology 2016
		NKG2A ligand overexpression	Higher levels of HLA-E expression are correlated with a poor prognosis in HCC patients	Human	Sun, <i>et al.</i> Oncoimmunology 2016
			Patients with HLA-E overexpression had the lowest long-term survival	Human	Zhen, <i>et al.</i> Medical Oncology
		TIGIT	High TIGIT expression was correlated with NK cell exhaustion in tumor-bearing mice and patients with colon cancer	Human	Zhang, <i>et al.</i> 2018 Nature Immunol
			Interactions with CD155 ligand-expressing target cells lead to reduction of DNAM-1 expression on NK cells	Human	Carlsten, <i>et al.</i> 2009 J Immunol
	NK cell inhibition by extracellular stimuli		TIGIT ligand overexpression	Breast cancer	Human
			Lung cancer	Human	Nakai, <i>et al.</i> 2010 Cancer Sci
		Hypoxia	Liver cancer	Human	Zheng, <i>et al.</i> 2019 Nature Immunol

Mechanism	Cause	Evidence	Cancer type	Species	Ref.
NK cell inhibition by immunosuppressive cells		H ₂ O ₂ produced within tumor microenvironments is inversely correlated with NK infiltration and impairs activity	Esophageal cancer	Human	Izawa, <i>et al.</i> 2011 Cancer Immunol Immunother,
		Infiltrating NK cells express low levels of activation receptors due to TGF- β -mediated inhibition	Glioblastoma	Human	Close, <i>et al.</i> 2019 Clinical and Experimental Immunology
	TGF- β production	TGF- β /SMAD signaling pathway was constitutively activated in ALL-NK cells	Acute lymphoblastic leukemia	Human	Rouce, <i>et al.</i> 2016 Leukemia
		High concentrations of TGF- β 1 present in the plasma of cancer patients were found to cause NKG2D downregulation	Lung and colorectal cancer	Human	Lee, <i>et al.</i> 2004 J Immunol
	Prostaglandin-E2 secretion	PGE2 produced by tumor-associated mesenchymal stem cells mediates NK cell inhibition	Lung cancer	Human	Galland, <i>et al.</i> 2017 Cell Reports
	Interleukin-dependent STAT3 activation	PGE2 promotes thyroid cancer progression by inhibiting NK cell maturation and cytotoxicity	Thyroid cancer	Human	Park, <i>et al.</i> 2018 Frontiers in Immunology
		Tumor cells activated the STAT3 signaling pathway, increasing IL-6 and IL-8 production, and inhibiting the activity and function of NK cells	Esophageal cancer	Human	Wu, <i>et al.</i> 2019 J Exp & Clin Cancer Research
	Regulatory T cells (Treg)	Inverse correlation between NK cell activation and expansion of the Treg cell population in tumor-bearing patients	Gastrointestinal stromal tumor	Human	Ghiringhelli, <i>et al.</i> 2005 J Exp Med
	Myeloid-derived suppressor cells	Autologous MDSC cells produce nitric oxide (NO), which inhibits NK cell-mediated ADCC	Melanoma, HNSCC and breast cancer	Human	Stiff, <i>et al.</i> 2018 Clin Cancer Res